Metrics as of 10/15/2026, 03:43 PM (Berlin time), refresh in progress.
Odyssey Therapeutics Stock
Odyssey Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Gary D. Glick
- Employees
- 100
- Market cap
- $804 M
- IPO
- 08/05/2026
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is…
Odyssey Therapeutics stock: price history
1D
+0.8%
1W
-7.6%
1M
-23.9%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
Not enough history for an assessment
Ask the agents about Odyssey Therapeutics
Analyst assessment of Odyssey Therapeutics
PRICE TARGET LOW
US$27.00
CONSENSUS
US$36.60
MEDIAN
US$40.00
PRICE TARGET HIGH
US$44.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 07/08/2026
Odyssey Therapeutics stock metrics
P/E
-6.56
P/B
1.2
EV/EBITDA
-8.42
RETURN ON EQUITY
-12.5%
NET MARGIN
0.0%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
55.9%
FLOAT SHARES
26,870,368
AVG. DAILY VOLUME (30D)
356,879
Insider transactions (SEC)
TPG GP A, LLC
TPG GP A, LLC
TPG GP A, LLC
TPG GP A, LLC
Dimension Capital II, L.P.
Institutional holders
Comparable stocks
Frequently asked questions about Odyssey Therapeutics stock
What does Odyssey Therapeutics do?
Odyssey Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Gary D. Glick, the company employs around 100 people.
The IPO was on 08/05/2026; the stock trades on NASDAQ under the ticker ODTX.
What do analysts say about Odyssey Therapeutics stock?
2 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$36.60, ranging from US$27.00 to US$44.00, with a median of US$40.00.
This is an external assessment, not a statement by Market Jury.
When does Odyssey Therapeutics report next?
The next earnings date is 04/11/2026.
Does Odyssey Therapeutics pay a dividend?
No, Odyssey Therapeutics currently does not pay a dividend.
Which stocks are comparable to Odyssey Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Odyssey Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Odyssey Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.